zw25,trastuzumab deruxtecan
zymeworks,daiichi sankyo,astrazeneca
['zw25']
herb ph 2 trial: t-dxd for her2+ btc orr 36.4% pfs 4.4 mo, os 7.1 mo g 3 in 81.3%, g 3 ild 12% her2 is a target in btc, t-dxd is active but toxicity was significant; zw25 trial ongoing (nct04466891) #asco22
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers